Oltipraz in the Prevention of Lung Cancer in People Who Smoke
Lung Cancer
About this trial
This is an interventional prevention trial for Lung Cancer focused on measuring non-small cell lung cancer, small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Current cigarette smokers At least 20 cigarettes a day No variation of more than 10 in the number of cigarettes smoked per day within the past 3 months At least 10 years of smoking any amount Failed to stop smoking after at least one attempt to quit within the last 3 years Prior stage I non-small cell lung cancer allowed if surgically resected with at least a lobectomy No concurrent evidence of lung cancer Willing to undergo 2 bronchoscopies PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 Life expectancy: Not specified Hematopoietic: CBC normal Hemostasis normal Hepatic: PT and PTT normal Renal: Blood chemistries normal Nonfasting glucose no greater than 200 mg/dL No active renal disease No urinary tract infection by urinalysis (trace protein allowed) Cardiovascular: EKG normal No coronary artery disease requiring continuous medication Pulmonary: Chest radiograph normal (postsurgical changes allowed) No acute or significant chronic abnormality FEV1 greater than 1.8 L or 75% predicted No chronic obstructive pulmonary disease requiring continuous medication Other: No known hypersensitivity or prior adverse reaction to oltipraz No inmates or prisoners No medical or psychological condition that would preclude study (e.g., acute psychosis) No prior malignancy except nonmelanomatous skin cancer, cervical dysplasia, or curatively treated stage I or II cancer of the head and neck Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 6 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 months since prior potential chemoprevention agent (e.g., oltipraz, retinoids, or acetylcysteine) Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics
Sites / Locations
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
- Duke Comprehensive Cancer Center